Monoclonal antibody · Kills target cells, directed at C-C chemokine receptor 8 (CCR8) · developed by Zai Lab
ZL-1218 is a humanized IgG1 monoclonal antibody that binds CCR8 on tumor-infiltrating regulatory T-cells in the tumor microenvironment. It depletes these cells through antibody-dependent cellular cytotoxicity and is being studied in malignant solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05859464 | Phase 1 | Malignant Solid Tumor | Terminated | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Malignant Solid Tumor
See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZLAB catalysts and pipeline →